Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Surface Oncology

Surface Oncology
2014 FOUNDED
PUBLIC STATUS
71-80 EMPLOYEES
SURF STOCK SYMBOL
$3.96 SHARE PRICE (As of Monday Closing)
Description

Surface Oncology Inc is a clinical-stage immuno-oncology company. It is developing new therapies that modify the spaces in and around tumors the tumor microenvironment to create conditions that support and sustain anti-tumor immune responses. The company's pipeline products are SRF231, SRF373, SRF617, and SRF388. Geographically, the activities are carried out through the region of the United States.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 50 Hampshire Street
  • 8th Floor
  • Cambridge, MA 02139
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Surface Oncology’s full profile, request a free trial.

Surface Oncology Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$3.45 - $18.18 $110M $4.00 -$1.72 57.4K 27.8M

Surface Oncology Financials Summary

In Thousands,
USD
TTM
31-Mar-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value (26,088) 54,062
Revenue 28,356 59,417 12,826 6,632
EBITDA (43,706) (7,804) (45,026) (17,673)
Net Income (42,008) (6,597) (45,377) (17,453)
Total Assets 170,608 174,065 81,454 98,139
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Surface Oncology Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Surface Oncology‘s full profile, request access.

Request full access to PitchBook

Surface Oncology Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Surface Oncology‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Surface Oncology Competitors (22)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Jounce Therapeutics Failed Transaction (M&A) Cambridge, MA 000 00000 000000&0
0000 000000000000 Formerly VC-backed Cambridge, MA 00 00000 000000000 00000
000000000000 Venture Capital-Backed Houston, TX 000.00 00000000000 000.00
0000 000000 Formerly VC-backed San Diego, CA 00 00000 000000000 00000
000000 000000 Formerly VC-backed Seattle, WA 00 00000 000000&0 00000
To view this company’s complete list of competitors, request access »

Surface Oncology Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Surface Oncology‘s full profile, request access.

Request full access to PitchBook

Surface Oncology Executive Team (12)

Name Title Board
Seat
Contact
Info
Jeffrey Goater Chief Executive Officer & Board Member
Vito Palombella Chief Scientific Officer
Shane Mulligan Executive
Arlene Sharpe Co-Founder & Scientific Board Advisor
Jessica Fees Senior Vice President of Finance and Business Operations

2 Former Executives

You’re viewing 5 of 12 executives. Get the full list »

Surface Oncology Board Members (13)

Name Representing Role Since Contact
Info
Armen Shanafelt Ph.D Lilly Ventures Board Member 000 0000
Chris Klee Self Board Observer 000 0000
Daniel Lynch Self Chairman 000 0000
David Grayzel MD Atlas Venture Board Member 000 0000
Detlev Biniszkiewicz Ph.D Self Board Member 000 0000

3 Former Board Members

You’re viewing 5 of 13 board members. Get the full list »